Artículo
Precision improvement for omeprazole determination through stability evaluation
Fecha de publicación:
01/2012
Editorial:
John Wiley & Sons Inc
Revista:
Drug Testing and Analysis
ISSN:
1942-7611
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
A new spectrofluorimetric method for the determination of omeprazole (OMP) based on its degradation reaction catalyzed by ultraviolet (UV) light is proposed. OMP in aqueous solution is very unstable, which renders a serious difficulty for controlling its quality. It does not show native fluorescence, but when exposed to UV radiation, it generates a highly fluorescent degradation product with adequate stability for indirect OMP quantification. Under the studied optimal experimental conditions (pH, temperature, exposure time to UV radiation), a specific rate constant of 2.851 min -1-described by zero-order kinetic-was obtained for the degradation reaction. Using λ exc 293 nm and λ em 317 nm, a linear relationship was obtained (r 2 0.9998) in the concentration range of 0.1 to 1.3 μg mL -1, with a detection limit of 1.07 10 -3 μg mL -1 (S/N = 3). The methodology developed was successfully applied to OMP quality control in pure drugs and tablet dosage forms without previous treatment, with good tolerance to common excipient, and a high level of concordance between the nominal and experimental values. This work constitutes an important contribution to knowledge of the degradation mechanism of OMP. It has been shown to be appropriate for OMP quality control, to have an adequate sampling rate, low cost instrument, and to be a less polluting procedure.
Palabras clave:
OMEPRAZOLE
,
QUALITY CONTROL
,
SENSITIZED FLUORESCENCE
,
UV DEGRADATION
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(INQUISAL)
Articulos de INST. DE QUIMICA DE SAN LUIS
Articulos de INST. DE QUIMICA DE SAN LUIS
Citación
Peralta, Cecilia Mariana; Fernandez, Liliana Patricia; Masi, Adriana Noemi; Precision improvement for omeprazole determination through stability evaluation; John Wiley & Sons Inc; Drug Testing and Analysis; 4; 1; 1-2012; 48-52
Compartir
Altmétricas